These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 9154316)

  • 21. [Emperipolesis in megakaryocytes in patients with thrombocytosis in the course of myeloproliferative disorders].
    Bobik R; Podolak-Dawidziak M; Kiełbiński M; Jeleń M; Wróbel T
    Acta Haematol Pol; 1995; 26(2):179-83. PubMed ID: 7653223
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heterogeneity of in vitro growth pattern of megakaryocyte progenitors (CFU-M) in myeloproliferative disorders.
    Hamaguchi H; Takano N; Sakamaki H; Enokihara H; Saito K; Furusawa S; Shishido H
    Eur J Haematol; 1988 Aug; 41(2):163-9. PubMed ID: 3410010
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Histological diagnosis of Ph-negative myeloproliferative neoplasia. An overview].
    Campr V
    Cesk Patol; 2011 Jul; 47(3):84-93. PubMed ID: 21887923
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Megakaryocytes in chronic myeloproliferative disorders: numerical density correlated between different entities.
    Kaloutsi V; Fritsch RS; Buhr T; Restrepo-Specht I; Widjaja W; Georgii A
    Virchows Arch A Pathol Anat Histopathol; 1991; 418(6):493-7. PubMed ID: 2058083
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regulation of megakaryocyte colony forming cell numbers and ploidy by dideoxynucleosides in immunodeficient mice.
    Chow FP; Ordóñez JV; Sutton PA; Hamburger AW
    Am J Hematol; 1993 Dec; 44(4):249-55. PubMed ID: 8237995
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The frequency and significance of megakaryocytic emperipolesis in myeloproliferative and reactive states.
    Cashell AW; Buss DH
    Ann Hematol; 1992 Jun; 64(6):273-6. PubMed ID: 1637881
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potential of bone marrow biopsy in chronic myeloproliferative disorders (MPD).
    Bartl R; Frisch B; Wilmanns W
    Eur J Haematol; 1993 Jan; 50(1):41-52. PubMed ID: 8436214
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Angiogenesis in chronic myeloproliferative diseases.
    Di Raimondo F; Palumbo GA; Molica S; Giustolisi R
    Acta Haematol; 2001; 106(4):177-83. PubMed ID: 11815715
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Density distribution and size of megakaryocytes in inflammatory reactions of the bone marrow (myelitis) and chronic myeloproliferative diseases.
    Thiele J; Holgado S; Choritz H; Georgii A
    Scand J Haematol; 1983 Oct; 31(4):329-41. PubMed ID: 6578591
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Platelet derived growth factor messenger RNA is increased in bone marrow megakaryocytes in patients with myeloproliferative disorders.
    Katoh O; Kimura A; Itoh T; Kuramoto A
    Am J Hematol; 1990 Nov; 35(3):145-50. PubMed ID: 2220756
    [TBL] [Abstract][Full Text] [Related]  

  • 31. WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders.
    Michiels JJ; De Raeve H; Hebeda K; Lam KH; Berneman Z; Schroyens W; Schwarz J
    Leuk Res; 2007 Aug; 31(8):1031-8. PubMed ID: 17367853
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinicopathology and histochemistry on bone marrow biopsies in chronic myeloproliferative disorders--a clue to diagnosis and classification.
    Thiele J; Kvasnicka HM
    Pathol Biol (Paris); 2001 Mar; 49(2):140-7. PubMed ID: 11317959
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circulating megakaryocyte progenitors in myeloproliferative disorders are hypersensitive to interleukin-3.
    Kobayashi S; Teramura M; Hoshino S; Motoji T; Oshimi K; Mizoguchi H
    Br J Haematol; 1993 Apr; 83(4):539-44. PubMed ID: 7686030
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interferon-alpha-induced morphological changes of megakaryocytes: a histomorphometrical study on bone marrow biopsies in chronic myeloproliferative disorders with excessive thrombocytosis.
    Chott A; Gisslinger H; Thiele J; Fritz E; Linkesch W; Radaszkiewicz T; Ludwig H
    Br J Haematol; 1990 Jan; 74(1):10-6. PubMed ID: 2310690
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro megakaryocyte differentiation and proplatelet formation in Ph-negative classical myeloproliferative neoplasms: distinct patterns in the different clinical phenotypes.
    Balduini A; Badalucco S; Pugliano MT; Baev D; De Silvestri A; Cattaneo M; Rosti V; Barosi G
    PLoS One; 2011; 6(6):e21015. PubMed ID: 21698292
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantitative analysis of growth factor production in the mechanism of fibrosis in agnogenic myeloid metaplasia.
    Wang JC; Chang TH; Goldberg A; Novetsky AD; Lichter S; Lipton J
    Exp Hematol; 2006 Dec; 34(12):1617-23. PubMed ID: 17157157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduced responsiveness of bone marrow megakaryocyte progenitors to platelet-derived transforming growth factor beta 1, produced in normal amount, in patients with essential thrombocythaemia.
    Zauli G; Visani G; Catani L; Vianelli N; Gugliotta L; Capitani S
    Br J Haematol; 1993 Jan; 83(1):14-20. PubMed ID: 8435322
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characteristics of circulating megakaryocyte progenitors (CFU-MK) in patients with primary myelofibrosis.
    Han ZC; Briere J; Nedellec G; Abgrall JF; Sensebe L; Parent D; Guern G
    Eur J Haematol; 1988 Feb; 40(2):130-5. PubMed ID: 3345826
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endogenous megakaryocytic colony formation and thrombopoietin sensitivity of megakaryocytic progenitor cells are useful to distinguish between essential thrombocythemia and reactive thrombocytosis.
    Mi JQ; Blanc-Jouvan F; Wang J; Sotto MF; Cousin F; Castinel A; Chauvet M; Sotto JJ; Polack B; Mossuz P
    J Hematother Stem Cell Res; 2001 Jun; 10(3):405-9. PubMed ID: 11454315
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.